Copyright © Inderes 2011 - present. All rights reserved.

Medicover

240

 

SEK

 

+0.42 %

Less than 1K followers

MCOV B

NASDAQ Stockholm

Health Care Providers

Health Care

+0.42%
-0.62%
+14.83%
+25%
+36.52%
+21.95%
+41.93%
+133.01%
+266.41%

Medicover operates in the healthcare industry. The company is an international healthcare and diagnostics company and focuses on providing medical services and laboratory analyses. The company's services are aimed at individuals and companies that need fast and accessible care. Medicover was founded in 1994 and is headquartered in Stockholm, Sweden.

Read more
Market cap
36.85B SEK
Turnover
26.1M SEK
Revenue
23.99B
EBIT %
3.36 %
P/E
186.83
Dividend yield-%
0.72 %
Financial calendar
24/7
2025

Interim report Q2'25

5/11
2025

Interim report Q3'25

ShowingAll content types
Third party research

Medicover: ABGSC Investor Days feedback - ABG

New CEO is continuing on the strong trajectory We expect 15% yearly organic growth for '25e-'27e Trades at ~13x '25e EV/EBITDA New CEO is not so new Today, we welcomed Medicover’s new CEO, Mr John Stubbington, to ABGSC’s Investor Days. This was one of...

Medicover

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Third party research

Medicover: Momentum still in motion - ABG

Strong Q1 with operational leverage driving margin expansion Adj. EBITDA up 4-5% for '25e-'27e after including recent M&A We keep our fair value range of SEK 180-260 Strong growth and margin expansion despite a flat India Medicover had a strong first...

Medicover
Third party research

Medicover: Improved operating leverage and growth - ABG

8%/9% adj. EBITDA vs ABGSCe/cons in Q1 Cons estimates likely up low to mid single digits on adj. EBITDA '25e Margin improvements driven by operational leverage Q1 results Medicover reported an adj. EBITDA beat in Q1 (8%/9% vs. ABGSCe/cons), with earnings...

Medicover
Third party research

Medicover: Set to continue on its growth trajectory - ABG

Q1'25 numbers due on 29 April at 07:45 CET Adj. EBITDA up by 1% for '25e-'27e Fair value range of SEK 180-260 kept intact Q1'25e expectations We expect Medicover to continue on its growth trajectory into 2025, driven by strength in both segments. In ...

Medicover
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.